Align Technology (ALGN)
(Real Time Quote from BATS)
$273.64 USD
-6.68 (-2.38%)
Updated May 16, 2024 03:52 PM ET
After-Market: $273.57 -0.07 (-0.03%) 4:10 PM ET
2-Buy of 5 2
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$273.64 USD
-6.68 (-2.38%)
Updated May 16, 2024 03:52 PM ET
After-Market: $273.57 -0.07 (-0.03%) 4:10 PM ET
2-Buy of 5 2
C Value C Growth C Momentum C VGM
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) on global expansion and strategic alliance.
What's in Store for Cooper Companies (COO) in Q4 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
Align Technology (ALGN) Up 14% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), led by its strong global presence.
CNMD or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CNMD vs. ALGN: Which Stock Is the Better Value Option?
Align Technology (ALGN) Q3 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Align Technology's (ALGN) Q3 fiscal 2023 performance reflects revenue growth across all regions.
Compared to Estimates, Align Technology (ALGN) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Align Technology (ALGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Align Technology (ALGN) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of -5.31% and 3.46%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on robust volume growth in the Plasma business and upbeat guidance.
Analysts Estimate West Pharmaceutical Services (WST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align (ALGN) Gains From New Launches, Strategic Partnerships
by Zacks Equity Research
Align Technology (ALGN) has well-established relationships with many DSOs, especially in the United States.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.
Align Technology (ALGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add Cencora (COR) to Your Portfolio Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
STERIS' (STE) Improved Volume, New Buyouts Drive Growth
by Zacks Equity Research
On the capital equipment side for STERIS (STE), the easing of supply-chain issues and reduced lead times are boosting shipments.
PetMeds (PETS) to Advance Pet Care With New Collaboration
by Zacks Equity Research
PetMeds (PETS) is positioning itself more firmly in the field of pet health and wellness as a result of its established reputation in the pet pharmaceutical industry.
Orthofix (OFIX) Secures FDA 510k Clearance for OsteoCove Graft
by Zacks Equity Research
Orthofix (OFIX) announces the full commercial availability of the OsteoCove synthetic graft after gaining the FDA's nod.
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) on the strength of the Critical Care business and TAVR sales.
Here's Why You Should Invest in Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD) on continued expansion in Omnipod's market access.
Alcon (ALC) Stock Up 9.7% YTD: Will the Rally Continue?
by Zacks Equity Research
Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Artivion (AORT) have performed compared to their sector so far this year.
Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod
by Zacks Equity Research
Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) due to its impressive acquisition deals and end-market strength.
Here's Why You Should Retain Fresenius Medical (FMS) for Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.